Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis
Metadatos
Mostrar el registro completo del ítemAutor
Sabin, Julia; Salas, Elisa; Martín-Martinez, Jesús; Candelilere-Merlicco, Antonio; Barrero Hernández, Francisco Javier; Alonso, Ana; Sánchez-Menoyo, José Luis; Borrega, Laura; Rodríguez-Rodríguez, María; Gómez Gutiérrez, Montserrat; Eichau, Sara; Hernández Pérez, Miguel Ángel; Calles, Carmen; Fernández-Díaz, Eva; Carmona, Olga; Orviz, Aida; López-Real, Ana; López-Muñoz, Pablo; Mendoza, Amelia; Agüera, Eduardo; Maurino, JorgeEditorial
Elsevier
Materia
Disease progression Patient-reported outcome measures Relapsing-remitting multiple sclerosis Uncertainty
Fecha
2024-09-03Referencia bibliográfica
J. Sabin et al. Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 91 (2024) 105861. https://doi.org/10.1016/j.msard.2024.105861
Patrocinador
Roche Medical Department, Spain (ML43469)Resumen
Background
Patients with multiple sclerosis (MS) have to deal with a variable disease trajectory often associated with disability and productivity loss.
Objective
This study aimed to assess illness-related uncertainty and associated correlates in patients with relapsing-remitting multiple sclerosis (RRMS) beyond the near diagnosis phase.
Methods
We conducted a multicenter, non-interventional study including patients diagnosed with RRMS (2017 revised McDonald criteria) and a disease duration of 3 to 8 years. Perceived uncertainty was measured using the Mishel Uncertainty of Illness Scale (MUIS). Associations between the MUIS and different patient-based outcome measures were analyzed using Spearman's rank correlation.
Results
A total of 201 patients were studied (mean age (standard deviation): 38.7 (8.4) years, 71.4 % female). The median disease duration (interquartile range) was 6.0 (4.0–7.0) years and the median EDSS score was 1.0 (0.0–2.0). The mean MUIS score was 38.2 (10.8). Perceived uncertainty was positively correlated with fatigue (p < 0.001), symptom severity (p < 0.001), anxiety (p < 0.001), depressive symptoms (p < 0.001), and a threatening illness perception (p < 0.001), and negatively correlated with self-management (p < 0.001), self-efficacy (p < 0.001), processing speed (p < 0.001), knowledge of MS (p = 0.006), and quality of life (p < 0.001).
Conclusion
Illness-related uncertainty was common in a population of mid-stage RRMS. Identifying uncertainty and its associated factors may be useful for implementing preventive strategies to help patients cope with the disease throughout life.





